Avenanthramides and Exercise

PepsiCo

Status: Completed

Conditions: Avenanthramides

Treatments: Other: Avenanthramides

Study type: Interventional

Funder types: Industry

Identifiers

NCT02584946

PEP-1513

Details and patient eligibility

About

The aim of the proposed study is to examine whether long-term dietary supplementation (8 weeks) of an oat flour cookie rich in avenanthramides (AVA) could enhance blood antioxidant capacity and reduce blood inflammatory markers after a downhill running (DR) protocol among human subjects.

Enrollment: 24 patients

Sex: All

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Male and female non-obese subjects (18kg/M2<BMI<28kg/M2) (age 20-45 years) will be recruited from the Twin Cities community. All participants will sign informed consent approved by UMN-IRB and are willing to avoid oat consumption and rigorous physical activity the day prior to and through test and to consume a low-polyphenol diet for 1 week prior to the study. The foods rich in polyphenols include all berries, apples, pears, citrus fruits, fruit juices, onions, chocolate, wine, coffee, tea, beans, nuts, soy products and most spices

Exclusion criteria

1. Presence of GI conditions that interfere with absorption;
2. Clinically significant endocrine, cardiovascular, pulmonary, renal, hepatic, pancreatic, biliary or neurologic disorders;
3. Major trauma or surgery within 3 months of visit;
4. Cancer in the prior 2 years;
5. Allergic to oat products;
6. Women who are pregnant or lactating;
7. Smoking;
8. Drinking alcohol >5 drinks/week;
9. Using nutraceuticals;
10. Blood pressure medication;
11. NSAID (>800 mg ibuprofen/week)
12. Vitamin supplementation
13. Anticoagulants or hypoglycemic drugs
14. Oat products consumption and rigorous physical activity the day before the test and consumption of a high-polyphenol diet in week prior to the test.
15. Moderate-intensity cardiorespiratory exercise training for ≥30 min•d-1 on ≥5 d•wk-1 for a total of ≥150 min•wk-1, vigorous-intensity cardiorespiratory exercise training for ≥20 min•d-1 on ≥3 d•wk-1 (≥75 min•wk-1), or a combination of moderate- and vigorous-intensity exercise to achieve a total energy expenditure of ≥500-1000 MET•min•wk-1

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

24 participants in 2 patient groups, including a placebo group

Low-AVA oat flour cookies

Placebo Comparator group

Treatment:

Other: Avenanthramides

High-AVA oat flour cookies

Experimental group

Treatment:

Other: Avenanthramides